A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care.

Trial Profile

A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms AKKA
  • Sponsors Karo Bio
  • Most Recent Events

    • 30 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 09 May 2012 Additional lead trial investigator (Santosh Jamboti) identified as reported by Clinical Trials Registry - India.
    • 22 Mar 2012 New source identified and integrated (CTRI2012-02-002413).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top